Empagliflozin for No-reflow Phenomenon in PCI for STEMI

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 162 participants.

Also called NCT06342141

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 162 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06342141
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06342141. Randomized; triple masking; primary purpose prevention. Start 2024-08-22 (actual); primary completion 2026-03-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Acronym
EMPA-PCI
Condition
STEMI
Condition
No-Reflow Phenomenon
Intervention (Drug)
Empagliflozin 25 milgrams (Mg)
Intervention (Drug)
Empagliflozin 10 Mg
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez (class: other)

Record details

Record id
cardio:ct-nct06342141
Content hash
797710ac89692eee11feacf31db96e5d2a8113d01da92b8948bde3bb10945fc0